Ascentage Pharma Group International (AAPG) Cash & Equivalents (2022 - 2025)

Ascentage Pharma Group International (AAPG) has reported Cash & Equivalents for 4 consecutive years, with $348.3 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents rose 180.1% year-over-year to $348.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $348.3 million (up 180.1% YoY) and the FY2025 annual result came in at $812000.0, down 99.36% from the prior year.
• Cash & Equivalents advanced to $348.3 million in Q4 2025 per AAPG's latest filing, from $231.9 million in the prior quarter.
• Over the last five years, Cash & Equivalents for AAPG reached as high as $348.3 million in Q4 2025 and fell as low as $3.4 million in Q4 2023.
• A 4-year average of $179.4 million and a median of $189.2 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 98.2% — and 2024, when it jumped 3548.41%.
• Year by year, Cash & Equivalents stood at $189.2 million in 2022, then tumbled by 98.2% to $3.4 million in 2023, then soared by 3548.41% to $124.3 million in 2024, then surged by 180.1% to $348.3 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $348.3 million, $231.9 million, and $124.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.